anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Glaucoma is a disease of the optic nerve, which results in structural optic nerve head (ONH) damage and functional visual field (VF) loss. It has increased as a cause of global blindness from 4.4% in 1990 to 6.3% in 2010. Its global prevalence is also increasing from 3.54% or 64.3 million people in 2013 to a projected 111.8 million people by 2040. Detection of structural ONH damage is critical for early diagnosis, because ONH changes usually precede VF loss. Two cornerstone elements of the ONH and peripapillary examination are stereo disc photography and optical coherence tomography (OCT) retinal nerve fiber layer (RNFL) thickness measurements. By analyzing the neuroretinal rim in disc photos of normal subjects, Jonas et al found that the rim width typically exhibited a specific pattern of the inferior (I) rim being the widest, followed by the superior (S) rim, then the nasal (N) rim, and then the temporal (T) rim being the thinnest. This specific neuroretinal rim pattern was later coined by Elliot Werner as the "ISNT rule." Because neuroretinal rim loss is a hallmark feature of glaucoma, patients who deviate from the ISNT rule may need to be watched more closely for glaucoma. The RNFL, on the other hand, has also been shown in histological studies in normal, non-glaucomatous eyes to exhibit a similar pattern of the inferior quadrant being the thickest, followed by the superior, nasal, then temporal quadrant. Since RNFL thinning, particularly in the superior and inferior quadrants, is also a characteristic structural change in glaucoma, deviation from the ISNT rule for RNFL thickness may also be an early indicator of glaucomatous structural change. Therefore, many investigators have sought to determine whether the ISNT rule, either applied to the neuroretinal rim disc photos or to RNFL thickness measurements, is useful in the diagnosis of glaucoma or not. However, the optic disc photo ISNT rule studies are conflicting, with some finding the ISNT rule and its variants clinically useful, while others have not. In contrast, RNFL ISNT rule studies based on OCT findings are in uniform agreement, stating that the ISNT rule and its variants were not helpful in the diagnosis of glaucoma. Some have hypothesized that the ISNT rule is not easily generalizable to the individual, because the initial studies were derived from mean values. Therefore, some of the limitations of the ISNT rule may stem from the fact that it is unclear what percentage of individual normal eyes follow the ISNT rule. Other limitations may arise from the fact that perhaps other rules may be more common in the normal population.
OBJECTIVES: Emergency cervical cerclage is a high-risk surgical procedure associated with maternal and fetal risks, including preterm birth. Authors have developed scores to try to predict the probability of success following emergency cerclage, but these tools have yet to be externally validated. Our main objective was to assess the preterm birth rate before 32 weeks following emergency cerclage. Secondary objectives included assessing perinatal outcomes and the predictive validity of two published scores in our setting. We hypothesized that predictive scores, such as Fuchs and Kokia scores, may not perform optimally in our population due to variability in clinical and biological characteristics that influence eligibility for cerclage across different settings.
STUDY DESIGN: We conducted a retrospective, monocentric study in a tertiary maternity hospital. All patients who underwent emergency cerclage between January 1st, 2010, and December 31st, 2021, were included. The main outcome was preterm birth rate before 32 weeks. Secondary outcomes were need for maternal hospitalization after initial hospitalization for cerclage, preterm premature rupture of membrane, and perinatal death. The rate of preterm birth before 32 weeks and adverse perinatal outcomes were estimated. To assess the predictive validity of Fuchs' score in our population, we performed a multivariable logistic regression model including the score's variables and constructed receiver operating characteristic (ROC) curve. To assess the validity of Kokia's score in our population, we studied the correlation between the initial score and gestational age at delivery using Pearson's correlation coefficient.
RESULTS: Our population was composed of 64 women who underwent an emergency cerclage. The median gestational age at delivery was 30.6 weeks (IQR (24.2; 37.6)). The preterm birth rate before 32 weeks was 54.7 %. The rate of perinatal death was 30.7 %. There were no statistical differences between the patients delivered before and after 32 weeks. The multivariable logistic regression model showed that none of the variables of Fuchs's score were significantly associated with preterm birth risk in our population. The AUC of the ROC curve using Fuchs' score was 0.63. There was a minor yet significant correlation between Kokia's score and gestational age at delivery (r = 0.26 - p = 0.04).
CONCLUSIONS: Our study underscores the persistent risks associated with cervical insufficiency, including very preterm birth. It highlights the variability in performance of predictive scores across different populations, underscoring the need for external validation in diverse clinical settings.
OCREVUS ZUNOVO can cause injection reactions, which can be local or systemic. Common symptoms of local injection reactions reported by patients treated with OCREVUS ZUNOVO in multiple sclerosis (MS) clinical trials included erythema, pain, swelling, and pruritus. Common symptoms of systemic injection reactions reported by patients included headache and nausea. In an open-label, active-controlled trial, injection reactions were more frequently reported with the first injection; 49% of patients experienced an injection reaction with the first injection [see Adverse Reactions (6.1)].

In MS clinical trials where ocrelizumab was administered intravenously, the incidence of infusion reactions in patients [who received methylprednisolone (or an equivalent steroid) and possibly other premedication to reduce the risk of infusion reactions prior to infusion] was 34% to 40%, with the highest incidence with the first infusion. There were no fatal infusion reactions, but 0.3% of intravenous ocrelizumab-treated MS patients experienced infusion reactions that were serious, some requiring hospitalization. Symptoms of infusion reactions can include pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, tachycardia, and anaphylaxis.

Monitor patients during and after injections [see Dosage and Administration (2.4)]. Inform patients that injection reactions can occur during or within 24 hours of the injection.

Reducing the Risk of Injection Reactions and Managing Injection Reactions

Administer oral premedication (e.g., dexamethasone or an equivalent corticosteroid, and an antihistamine) at least 30 minutes prior to each OCREVUS ZUNOVO injection to reduce the risk of injection reactions. The addition of an antipyretic (e.g., acetaminophen) may also be considered [see Dosage and Administration (2.3)].

Management recommendations for injection reactions depend on the type and severity of the reaction. For life-threatening injection reactions, immediately and permanently stop OCREVUS ZUNOVO and administer appropriate supportive treatment. For less severe injection reactions, the injection should be interrupted immediately, and the patient should receive symptomatic treatment. The injection should be completed at the healthcare provider's discretion and only after all symptoms have resolved.
The application concerns a method for corrective surgery of defects being amenable to rectification by the augmentation of tissue subjacent to the defect. The method involves retrieving viable cells from a subject, a neonate or human fetus. The cells are then cultured in vitro and placed into a tissue of the subject, the tissue being located in a position subjacent to the defect to be rectified. Alternatively, the cells may be cultured in a collagen matrix or suspended in a collagen matrix prior to being placed in a position subjacent to the defect to be rectified. In a further embodiment, the cells are cultured and the in vitro produced extracellular matrix is collected and placed in a position subjacent to the defect to be rectified. A method for the correction of vocal cord defects is also disclosed.
The invention relates to azithromycin composite freeze-dried powder for injection. The composite is prepared by dissolving azithromycin, phosphoric acid and disodium hydrogen phosphate into water for injection and freeze-drying the mixture. The molar ratio of azithromycin to phosphoric acid to disodium hydrogen phosphate is 1:2-2.05:0.02-0.1, preferably 1:2.01-2.05:0.05-0.1. The main granularity of the azithromycin composite freeze-dried powder for injection is between 300 and 500nm, preferably between 350 and 450nm. The distribution dispersion of the azithromycin composite freeze-dried powder for injection is between 100 and 150nm, preferably between 110 and 135nm. The azithromycin composite freeze-dried powder of the invention has excellent redissolution property and stability.
One hundred (100) healthy volunteers, 50 normal weight (NW) and 50 overweight (OW), age 6-30 will be recruited for the current study. All participants and/or their parents will sign informed consent prior to their participation. Participants will visit the clinic 4 times, with a week's difference between them. Participants will arrive at the clinic after 12 hours of fasting and avoiding physical activity for 14 hours. During the first visit, their RMR will be measured, and 15min later they will perform 60 min of aerobic training, and 15 minutes later they will be asked to drink 300ml of water, followed by a second RMR test. In the consecutive visits they will follow the same routine without the first RMR test, and drink either carbohydrate enriched shake, protein enriched shake or fat enriched shake; in a random order.
The most characteristic feature of obesity is the increase in adipose tissue. On the contrary, in anorexia nervosa, there is a decrease in adipose tissue enough to impair neuroendocrine functions. Adipose tissue is formed by loosely binding lipid-filled cells called adipocytes and is now considered an important part of energy metabolism. Adipokines it secretes play a role in many physiological processes of the body such as nutrition, appetite, energy balance, insulin, and glucose metabolism, lipid metabolism, regulation of blood pressure, vascular remodeling, coagulation, and inflammation.

Therefore, changes in the amount of body fat in these two patient groups, which are at the two ends of the spectrum, affect both the biochemical parameters and physiological functions of the patients in different ways. It is expected that both adipokine levels and biochemical parameters will approach the values of healthy subjects with a decrease in adipose tissue of clinically morbidly obese patients and an increase in adipose tissue of patients with AN. However, in some studies comparing the parameters of patients with constitutionally weak patients and patients with AN, results contrary to expectations were obtained. In this study, we compared the extent to which weight changes changed adipokines and correlated with biochemical parameters based on healthy and normal-weight volunteers.
This is a double-blind, randomized, parallel-group, placebo- controlled Phase 2 study to evaluate the safety and activity of subcutaneous (SC) MNTX versus SC placebo in participants who have undergone orthopedic procedures and who are expected to require opioids for 1 week after randomization. Participants will sign an informed consent form and be screened between Days 4-10 after their orthopedic procedure. Those participants who meet all eligibility requirements will be enrolled in the study. Treatment with study medication will be continued until either the participant no longer requires opioid medication for pain relief or the maximum number of doses is reached. Originally, participants were receiving treatment for up to 7 days. Then after Protocol Amendment 1 (12 March 2008), the duration of treatment changed from "up to 7 days" to "up to 4 days".
OBJECTIVE: To compare the clinical and radiological outcomes of limited discectomy (LD) and aggressive discectomy (AD) performed via spinal endoscopy using the transforaminal approach in patients with lumbar disc herniation(LDH) METHODS: We conducted a retrospective review of patients who underwent percutaneous endoscopic transforaminal discectomy (PETD) at the L4-L5 lumbar spine segments in our department from January 2017 to December 2020. The follow-up period extended to 24 months postoperatively. Patients were categorized into the LD and AD groups based on the extent of intraoperative disc removal. We retrospectively collected and analyzed clinical and radiological data.
RESULTS: The study followed 65 patients, with 36 in the LD group and 29 in the AD group. No statistically significant differences were noted in recurrence rates, the excellent and good Macnab rates, preoperative Disc Height Index (DHI), and preoperative Modic changes between the groups (P >0.05). However, significant differences were observed in operation duration, postoperative DHI and postoperative Modic change (P<0.05). No significant differences in Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) scores were detected between the groups preoperatively, or one and two years postoperatively (P>0.05). Nevertheless, notable differences in VAS and ODI scores were present one month postoperatively (P<0.05).
CONCLUSION: As a conventional surgical method for treating LDH, PETD can achieve satisfactory clinical results in both LD and AD, with no significant variance in recurrence rates. However, AD is associated with longer operation times, and greater postoperative reductions in DHI and greater postoperative Modic changes compared to LD.
Considering the limited efficacy of current therapies in lung, colorectal, and pancreatic cancers, innovative combination treatments with diverse mechanisms of action are needed to improve patients' outcomes. Chitinase-3 like-1 protein (CHI3L1) emerges as a versatile factor with significant implications in various diseases, particularly cancers, fostering an immunosuppressive tumor microenvironment for cancer progression. Therefore, pre-clinical validation is imperative to fully realize its potential in cancer treatment. We developed phage display-derived fully human monoclonal CHI3L1 neutralizing antibodies (nAbs) and verified the nAbs-antigen binding affinity and specificity in lung, pancreatic and colorectal cancer cell lines. Tumor growth signals, proliferation and migration ability were all reduced by CHI3L1 nAbs in vitro. Orthotopic or subcutaneous tumor mice model and humanized mouse model were established for characterizing the anti-tumor properties of two CHI3L1 nAb leads. Importantly, CHI3L1 nAbs not only inhibited tumor growth but also mitigated fibrosis, angiogenesis, and restored immunostimulatory functions of immune cells in pancreatic, lung, and colorectal tumor mice models. Mechanistically, CHI3L1 nAbs directly suppressed the activation of pancreatic stellate cells and the transformation of macrophages into myofibroblasts, thereby attenuating fibrosis. These findings strongly support the therapeutic potential of CHI3L1 nAbs in overcoming clinical challenges, including the failure of gemcitabine in pancreatic cancer.
Treatment of migraine and headaches can be performed by the use of potassium channel blockers. The potassium channel blockers block KATp channels and/or BK channels. Also disclosed are the potassium channel blockers in the manufacture of a medicament for the treatment of migraine or headache. In respect of the KATP channels the potassium channel blocker may blocks channels with SUR2B subunits e.g. channels with SUR2B and Kir6.1 subunits. In respect of BKGa channels, any of the α- or β-subunits of the channels may be blocked by a potassium channel blocke in the treatment of migraine and headaches.
From September 2021 to March 2023, a total of 80 diabetic foot ulcer patients admitted to Department of Endocrinology and Metabolism at the Affiliated Hospital of Nantong University were recruited. Participants are randomized in a ratio of 1: 1: 1:1 into four treatment groups of 20 participants: (i) standardized western medicine treatment group, (ii) standardized western medicine treatment+TNTL tablet+TNTL cream group , (iii) standardized western medicine treatment+TNTL tablet group, and (iiii) standardized western medicine treatment+TNTL cream group. Treatment with TNTL tablets: the oral administration of TNTL tablets, 4 tablets each time, 3 times a day. Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing. Anthropometric parameters, serum biochemical index, glycosylated hemoglobin, urinary microalbumin/creatinine ratio, islet-specific autoantibodies(ISAs), fat mass, and islet β-cell function were measured. The healing stage of the wound surface and the growth degree of granulation tissue were graded, and the time required for wound repairing to each healing stage was observed.
AIM: To identify mtDNA and OGG1 as potential biomarker candidates for mechanical asphyxia.
METHOD: The human tissues are divided into experimental group (hanging and strangulation) and control groups (hemorrhagic shock, brain injury group, and poisoning group). Detected the expression of OGG1 and integrity of mtDNA in cardiac tissue of each group. We used over-OGG1 vector and siRNA-OGG1 transfecting H9C2 cell line to observe the function of OGG1 in hypoxic cells.
RESULTS: 1. mtDNA integrity decreased in the mechanical asphyxia group, OGG1 expression increased in mechanical asphyxia groups. They can be biomarkers for mechanical asphyxia. 2. OGG1 increased first and decreased in hypoxia-induced H9C2 cells. OGG1 upregulated the TFAM, NRF1, and Bcl2 in hypoxia-induced H9C2. OGG1 downregulated cleaved-Caspase3 in hypoxia-induced H9C2 cells. 3. In the normoxia condition, NAC maintained mtDNA integrity and decreased the mitochondrial membrane potential and amount of ATP.
CONCLUSION: mtDNA integrity and OGG1 expression can be biomarkers for mechanical asphyxia. OGG1 can maintain mtDNA integrity and maintain the stability of the mitochondrial membrane.
Participants in the Counseling Only condition will receive the same manualized counseling sessions that are included in the T-STEP program. Specifically, 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
Myofascial Pain Syndrome (MAS) is a common condition encountered in the daily practice of musculoskeletal medicine. Dry needling is a commonly used technique by clinicians in the treatment of myofascial trigger points. Dry needling can be classified into two main categories based on the depth of needle insertion: superficial and deep dry needling. Dry needling can be performed using either manual palpation techniques or ultrasonographic imaging. Ultrasound allows for more precise needle placement. It must be recognized that the depth of needling (superficial insertion vs. deep insertion) varies for every structure and that without ultrasound guidance, differentiation between needling into the superficial fascia and beyond the deep fascia maybe difficult. In clinical settings, using ultrasound can help visualize the different layers and guide the needle to the appropriate depth. The aim of this study is to compare the effectiveness of deep fascia and intramuscular trigger point dry needling techniques, guided by ultrasound, on pain, disability, functional impairment, and quality of life in patients diagnosed with myofascial pain syndrome of the upper trapezius muscle.
PROBLEM TO BE SOLVED: To obtain an ADP(adenosine diphosphate)-ribosylation inhibitor particularly useful for treatment for H.pylori infectious disease by formulating a carbostyril derivative as an active ingredient. SOLUTION: This ADP-ribosylation inhibitor is obtained by formulating a carbostyril derivative [e.g. 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl propionic acid] of the formula (R is a halogen, and the substituent on the carbostyril skeleton is substituted in the 3-or 4-position and the linkage between 3-and 4-positions on the carbostyril skeleton is a single or double bond) as an active ingredient. A compounded agent prepared by mixing the above carbostyril derivative with an antibiotic (e.g. clarithromycin and the like) is particularly useful as a therapeutic agent for H.pylori infectious disease. The above carbostyril derivative is formulated in a proportion of 1-70wt.% based on the whole composition of medicine.
Gastric cancer represents one of the common malignant tumors in China, with high incidence and mortality rates. Surgery is the conventional treatment option for early and intermediate stage gastric cancer, but the diagnosis in the early stage of gastric cancer remains a challenge to clinical practitioners. Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA with an average size of 166 bp, mixed with cell-free DNA (cfDNA) of other sources in blood circulation. ctDNA is reflecting the most up-to-date status of the tumor genome. Hence, it is considered as a novel biomarker for tumors, which can be qualitative, quantitative, and used for disease monitoring. This study is designed to evaluate the potential clinical utility of circulating tumor DNA (ctDNA) as a clinical index in the diagnosis and prognosis of gastric cancer. The primary purpose of this trial is to describe the profile of ctDNA methylation in gastric cancer. The second purpose is to demonstrate the correlation between the plasma ctDNA methylation status and the diagnosis and prognosis of patients with early and intermediate stage gastric cancer.